Close menu




April 7th, 2025 | 07:30 CEST

100% price opportunity or short attack? Deutz, Bayer, Power Metallic Mines

  • Mining
  • Nickel
  • Copper
  • Commodities
  • Pharma
Photo credits: pixabay.com

Tension is rising at Deutz! While analysts are significantly raising their target price, short sellers are getting into position. Is it worth getting back in now? After all, the share price has corrected significantly. An interesting entry opportunity currently seems to be emerging at Power Metallic Mines. Under the name Power Nickel, the Company made headlines in 2024. Drilling uncovered not only massive nickel deposits but much more - and this is said to be just the beginning. The current price decline is an opportunity. In contrast, Bayer is simply unable to escape the negative headlines. The legal disputes will likely last at least until 2026. Nevertheless, analysts recommend buying the stock.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: DEUTZ AG O.N. | DE0006305006 , BAYER AG NA O.N. | DE000BAY0017 , POWER METALLIC MINES INC. | CA73929R1055

Table of contents:


    Power Metallic Mines: Strong drilling results point to rising share price

    In 2024, the Company caused a sensation with its Power Nickel project. Spectacular drilling results had turned the NISK project in Canada into a world-class multi-metal project. Not only were large quantities of nickel and copper discovered, but also platinum, gold, and silver. This led to the renaming of the Company as Power Metallic Mines. The net present value is already estimated by experts at around CAD 1.15 billion – while the market capitalization is currently below CAD 230 million – and the Company intends to increase it further. The entire area has not yet been explored by far. Even before the recent price correction, Power Metallic had raised around CAD 50 million through a capital increase to expand its drilling program and is fully financed until the end of 2026. This should result in a lot of news flow in the current year, and the chances are good that the stock will continue to cause a stir again in 2025.

    Three drills are currently in use. The expansion is currently underway, including a complete renewal of the core logging system. From June, the Company plans to search for new resources with six drills. The Company is very confident about this. Although huge deposits have already been discovered, the Company is confident that the 2025/2026 exploration campaigns will lead to further discoveries. Power Metallic will continue to use the "Ambient Noise Tomography" method. This significantly increases the accuracy of drilling and makes it possible to efficiently develop sulfide deposits.

    The latest drill results are also promising. Drill hole PN-24-093 returned 0.13 g/t gold, 2.74 g/t silver, 0.37% copper, 1.16 g/t palladium, 0.18 g/t platinum, and 0.09% nickel. Hole PN-24-086 returned a sensational 65.09 g/t palladium over a 1.55 m interval. Drill hole PN-24-094 also provided the first evidence of massive nickel-copper sulphides in the "Tiger" zone. If the positive drilling results continue, the price should soon move back towards its all-time high of around CAD 1.9 – 50% above its current level.

    Deutz: 70% upside or short attack?

    Last week, it finally hit the Deutz stock. Within 14 days, it lost around 23% of its value – the bulk of it at the end of last week. On Friday, Deutz shares entered the weekend at EUR 5.81. Does this mean that the "healthy" consolidation is now over? After all, the stock is still trading around 40% above its level at the beginning of the year.

    Warburg Research believes that the Deutz share is undervalued at its current level. The analysts recommend buying the share and now see upside potential again. In their update on the occasion of the annual figures, they had raised the price target for the Deutz share from EUR 7.60 to EUR 11.80.

    But caution is advised. Because as with several other profiteers of the German government's billion-euro package, short sellers are also building positions at Deutz. Most recently, for example, Qube Research & Technologies Limited reported that it holds a short position of 1.74% in Deutz shares.

    Bayer: Buy recommendation despite ongoing glyphosate fiasco

    Bayer currently has bigger problems than tariff uncertainty. The Leverkusen-based company urgently needs new blockbusters to replace the declining sales of its top sellers, Xarelto (anticoagulant) and Eylea. But time and money are in short supply. And the never-ending legal battles in the US – particularly over glyphosate – continue to overshadow everything and tie up resources.
    Recently, Bayer has at least strengthened its oncology pipeline. It has acquired the exclusive worldwide license for an MTA-compatible PRMT5 inhibitor from Puhe BioPharma for the selective treatment of MTAP-deleted tumors. However, the project is only in a Phase 1 study, and it will be a long time before a possible market approval.

    Puhe BioPharma CEO Yongqi Guo commented: "We see great potential for MTA-cooperative PRMT5 inhibitors in the treatment of MTAP-deleted tumors. Our MTA-cooperative PRMT5 inhibitor PH020, now known as BAY 3713372, has shown competitive selectivity for MTA-bound PRMT5, as well as activity and brain penetration in preclinical studies."

    At least there was a positive analyst comment recently. DZ Bank, for example, confirmed its "Buy" recommendation for Bayer shares. Even though the US Supreme Court is not expected to rule on glyphosate until the end of 2026, investors should take advantage of the historically low level. DZ analysts see Bayer's shares as being worth EUR 30. The stock is currently trading at around EUR 20.


    Buying Bayer shares does not seem compelling right now. An end to the litigation is still not in sight and the pharmaceutical pipeline is anything but promising. In contrast, the Power Metallic Mines share offers an interesting entry point after the recent price decline. If the positive news flow continues, significantly higher prices should be possible. At Deutz, the rally appears to be over for now.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Carsten Mainitz on November 18th, 2026 | 05:32 CET

    Commodities, Steel and SpaceX: A Look at the Opportunities in Strategic Resources, thyssenkrupp and Singulus

    • Commodities
    • Iron ore
    • Pellets
    • Green steel
    • Vanadium
    • Titanium
    • Solar
    • Opportunities
    • Investments

    A SpaceX order sends Singulus shares soaring. thyssenkrupp is driving forward its transformation into a pure financial holding company by spinning off materials distributor and service provider tk accelis and making the value of its holdings visible on the stock market. Strategic Resources, meanwhile, starts earlier in the industrial value chain. With high-purity iron ore pellets as well as vanadium, iron and titanium, the company aims to position itself as a raw materials supplier for lower-emission steel production and other future applications. Which share will come out ahead next year?

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Nico Popp on November 18th, 2026 | 05:28 CET

    Copper at a crossroads: BHP produces less, Siemens Energy reports record orders – and Power Metallic Mines positions itself for growth

    • Copper
    • Data centres
    • Market
    • Electrification

    Created and published on behalf of Power Metallic Mines

    Copper is becoming cheaper, even though the major mines are supplying less and grid equipment suppliers are reporting record orders. How does that add up? On the London Metal Exchange, the price of the red metal temporarily fell to around USD 13,515 per tonne on November 13, its lowest level since July. Goldman Sachs sees the main reason as investor positioning around AI stocks, not weaker physical demand. The bank therefore considers its forecast of USD 15,400 per tonne for 2027 potentially too high and sees USD 14,500 to 14,600 per tonne as more likely. A different picture emerges in industry: major mine operators are producing less because ore grades are declining and accidents or strikes are slowing extraction. At the same time, power grid equipment suppliers are reporting record orders. A high-grade copper deposit in Canada aims to fill this gap between falling mine supply and rising demand.

    Read